ALMR

Alamar Biosciences, Inc.

Nasdaq · CIK 0002104204
$22.00 -0.86% $1.5B
Insider Buying Cluster (2 insiders)High Impact Filing (8/10)
Vol
Market Cap$1.5B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (80%)
Insider Activity2B / 0S
Insider Net $$8.0M
Reddit Sentiment67° Warm
SEC Reports15
Exchange Nasdaq·CIK 0002104204·Prev Close $22.19

Recent Activity

May 8, 2026 SEC
Alamar Biosciences reported Q1 2026 revenue of $26.0M, a 99% YoY increase, driven by 178% consumable revenue growth. Net
8-K — Impact 8/10
May 8, 2026 SEC
Alamar Biosciences reported Q1 2026 revenue of $26.0M, up 99% YoY from $13.1M, driven by 178% consumable growth and 78%
PRESS-RELEASE — Impact 7/10
May 8, 2026 earnings
Alamar Biosciences Reports First Quarter 2026 Financial Results
<p>FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a le
Apr 22, 2026 SEC
Alamar Biosciences insiders and a major shareholder jointly purchased $8 million in stock, with Director Naclerio and 10
CLUSTER — Impact 7/10
Apr 20, 2026 Insider
Naclerio Nicholas acquired 4,588,364 shares
Director
Apr 20, 2026 Insider
Naclerio Nicholas disposed of 5,510,516 shares
Director
Apr 20, 2026 Insider
Naclerio Nicholas acquired 5,510,516 shares
Director

Price Targets

$30.00 +36.4% upside Strong Buy
Current $22.00 Low $27.00 Median $30.00 High $35.00 5 analysts
$27.00 $35.00

Analyst Ratings

Strong Buy80% buy · 10 analysts
3Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 12, 2026 Leerink Partners INITIATE Outperform
May 12, 2026 TD Cowen INITIATE Buy
May 12, 2026 JP Morgan INITIATE Overweight
May 12, 2026 Stifel INITIATE Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.32 $-0.40 — $-0.21 4
Next Q $-0.21 $-0.26 — $-0.12 4
Current FY $-1.46 $-1.65 — $-1.24 4
Next FY $-0.70 $-0.90 — $-0.48 52% YoY 4

Latest Reports

BULLISH 8-K 8/10
Alamar Biosciences reported Q1 2026 revenue of $26.0M, a 99% YoY increase, driven by 178% consumable revenue growth. Net
May 8, 2026
BULLISH PRESS-RELEASE 7/10
Alamar Biosciences reported Q1 2026 revenue of $26.0M, up 99% YoY from $13.1M, driven by 178% consumable growth and 78%
May 8, 2026

Recent Insider Trades

DateInsiderTypeValue
Apr 20, 2026Naclerio NicholasC$0.00
Apr 20, 2026Naclerio NicholasJ$0.00
Apr 20, 2026Naclerio NicholasJ$0.00
Apr 20, 2026Naclerio NicholasC$0.00
Apr 20, 2026Naclerio NicholasBUY$4.0M

Reddit Sentiment

67°
Warm
Bearish Neutral Bullish
2 mentions 2 bullish 0 bearish
∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

9 unique insiders with 50 transactions. Net insider value: $8.0M ($8.0M bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Apr 20, 2026Naclerio NicholasDirectorCONVERT4,588,364——
Apr 20, 2026Naclerio NicholasDirectorJ5,510,516——
Apr 20, 2026Naclerio NicholasDirectorJ5,510,516——
Apr 20, 2026Naclerio NicholasDirectorCONVERT346,020——
Apr 20, 2026Naclerio NicholasDirectorBUY235,294$17.00$4.0M
Apr 20, 2026Naclerio NicholasDirectorAWARD5,686——
Apr 20, 2026McAnear Justin J.Chief Financial OfficerAWARD37,220——
Apr 20, 2026Luo YulingChief Executive OfficerCONVERT1,386,746——
Apr 20, 2026Luo YulingChief Executive OfficerJ1,864,065——
Apr 20, 2026Naclerio NicholasDirectorCONVERT3,194,377——
Apr 20, 2026Naclerio NicholasDirectorCONVERT2,862,507——
Apr 20, 2026Naclerio NicholasDirectorCONVERT2,094,266——
Apr 20, 2026Naclerio NicholasDirectorCONVERT5,037,783——
Apr 20, 2026Naclerio NicholasDirectorCONVERT5,000,000——
Apr 20, 2026McAnear Justin J.Chief Financial OfficerJ570,719——
Apr 20, 2026Luo YulingChief Executive OfficerJ1,864,065——
Apr 20, 2026Luo YulingChief Executive OfficerAWARD76,509——
Apr 20, 2026Luo YulingChief Executive OfficerCONVERT1,020,742——
Apr 20, 2026Luo YulingChief Executive OfficerCONVERT880,802——
Apr 20, 2026Luo YulingChief Executive OfficerCONVERT366,004——
Apr 20, 2026Luo YulingChief Executive OfficerJ266,311——
Apr 20, 2026Luo YulingChief Executive OfficerJ42,334——
Apr 20, 2026Chen ShipingChief Operating OfficerCONVERT320,511——
Apr 20, 2026Chen ShipingChief Operating OfficerJ722,885——
Apr 20, 2026Chen ShipingChief Operating OfficerJ722,885——
Apr 20, 2026Chen ShipingChief Operating OfficerAWARD37,220——
Apr 20, 2026Chen ShipingChief Operating OfficerCONVERT247,311——
Apr 20, 2026Chen ShipingChief Operating OfficerCONVERT73,200——
Apr 20, 2026Chen ShipingChief Operating OfficerCONVERT176,160——
Apr 20, 2026Chen ShipingChief Operating OfficerJ300,883——
Apr 20, 2026Chen ShipingChief Operating OfficerJ12,190——
Apr 20, 2026White Timothy OgdenPresidentJ454,583——
Apr 20, 2026White Timothy OgdenPresidentAWARD37,220——
Apr 20, 2026White Timothy OgdenPresidentJ454,583——
Apr 20, 2026White Timothy OgdenPresidentJ29,357——
Apr 20, 2026Witney FrankDirectorJ49,627——
Apr 20, 2026Chambers RebeccaDirectorJ140,612——
Apr 20, 2026Illumina Innovation Fund II GP, L.L.C.10%+ OwnerCONVERT4,588,364——
Apr 20, 2026Illumina Innovation Fund II GP, L.L.C.10%+ OwnerJ5,510,516——
Apr 20, 2026Illumina Innovation Fund II GP, L.L.C.10%+ OwnerJ5,510,516——
Apr 20, 2026Illumina Innovation Fund II GP, L.L.C.10%+ OwnerCONVERT346,020——
Apr 20, 2026Illumina Innovation Fund II GP, L.L.C.10%+ OwnerCONVERT5,000,000——
Apr 20, 2026Illumina Innovation Fund II GP, L.L.C.10%+ OwnerBUY235,294$17.00$4.0M
Apr 20, 2026Illumina Innovation Fund II GP, L.L.C.10%+ OwnerCONVERT3,194,377——
Apr 20, 2026Illumina Innovation Fund II GP, L.L.C.10%+ OwnerCONVERT2,862,507——
Apr 20, 2026Illumina Innovation Fund II GP, L.L.C.10%+ OwnerCONVERT2,094,266——
Apr 20, 2026Illumina Innovation Fund II GP, L.L.C.10%+ OwnerCONVERT5,037,783——
Apr 20, 2026Qiming Corporate GP VI, Ltd.10%+ OwnerCONVERT113,625——
Apr 20, 2026Qiming Corporate GP VI, Ltd.10%+ OwnerCONVERT154,425——
Apr 20, 2026Qiming Corporate GP VI, Ltd.10%+ OwnerJ185,163——
15 SEC filing reports analyzed. Sentiment: 10 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 5.6/10.
BULLISH 8-K 8/10
Alamar Biosciences reported Q1 2026 revenue of $26.0M, a 99% YoY increase, driven by 178% consumable
May 8, 2026
BULLISH PRESS-RELEASE 7/10
Alamar Biosciences reported Q1 2026 revenue of $26.0M, up 99% YoY from $13.1M, driven by 178% consum
May 8, 2026
BULLISH CLUSTER 7/10
Alamar Biosciences insiders and a major shareholder jointly purchased $8 million in stock, with Dire
Apr 22, 2026
BULLISH EFFECT 7/10
Alamar Biosciences' IPO registration has become effective, allowing the company to begin selling sha
Apr 21, 2026
BULLISH CLUSTER 7/10
Two insiders at Alamar Biosciences, Inc. (ALMR) — Director Nicholas Naclerio and 10% owner Illumina
Apr 21, 2026
BULLISH 8-K 8/10
Alamar Biosciences completed its IPO, raising approximately $219.9 million by selling 12,937,500 sha
Apr 20, 2026
BULLISH 424B4 7/10
Alamar Biosciences has priced its IPO of 11.25 million shares at $17.00 per share, raising $177.9 mi
Apr 17, 2026
BULLISH EFFECT 7/10
Alamar Biosciences' IPO registration has become effective, allowing the company to begin selling sha
Apr 17, 2026
NEUTRAL 3 2/10
Frank Witney, a reporting person at Alamar Biosciences, filed a Form 3 to report initial beneficial
Apr 17, 2026
NEUTRAL 3 2/10
Ian W. Ratcliffe, a reporting owner at Alamar Biosciences, Inc., filed a Form 3 to report his initia
Apr 17, 2026
NEUTRAL 3 2/10
Rebecca Chambers, a director or officer of Alamar Biosciences, filed a Form 3 to report initial bene
Apr 17, 2026
NEUTRAL 3 3/10
Nicholas Naclerio, a director of Alamar Biosciences (ALMR), filed a Form 3 to report beneficial owne
Apr 17, 2026
NEUTRAL 3 3/10
Justin J. McAnear, CFO of Alamar Biosciences, filed a Form 3 disclosing an initial grant of stock op
Apr 17, 2026
BULLISH S-1/A 7/10
Alamar Biosciences is conducting an IPO to raise capital, leveraging strong revenue growth (196% YoY
Apr 16, 2026
BULLISH S-1/A 7/10
Alamar Biosciences is conducting an IPO to raise capital, leveraging strong revenue growth (195% YoY
Apr 13, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (80% buy). Based on 10 analysts: 3 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$30.00 mean target +36.4% upside Strong Buy (1.60)
$27.00 Low $35.00 High
MetricValue
Current Price$22.00
Target Low$27.00
Target Mean$30.00
Target Median$30.00
Target High$35.00
# Analysts5
RecommendationStrong Buy (1.60)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.32 $-0.40 $-0.21 — — — $0.0B — 4
Next Q
2026-09-30
 $-0.21 $-0.26 $-0.12 — — — $0.0B — 4
Current FY
2026-12-31
 $-1.46 $-1.65 $-1.24 — — — $0.1B — 4
Next FY
2027-12-31
 $-0.70 $-0.90 $-0.48 51.7% — — $0.2B 43.1% 4

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.322
7d ago$0.000-0.322
30d ago$0.000-0.322
60d ago$0.000-0.322
90d ago$0.000-0.322
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 12, 2026 Leerink Partners INITIATE — Outperform
May 12, 2026 TD Cowen INITIATE — Buy
May 12, 2026 JP Morgan INITIATE — Overweight
May 12, 2026 Stifel INITIATE — Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20263520080%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

67°
Warm
Bearish Neutral Bullish
2 mentions 2 bullish 0 bearish 2 time periods

Reddit Sentiment History

DateMentionsSentimentBullishBearishThreads
Apr 25, 2026160° Warm101
Apr 25, 2026160° Warm101

Recent Reddit Threads

r/stocks Bullish 1mo ago
Biggest insider buys this week
▲ 1 💬 0 ⚡ 0.5
May 8, 2026
earnings
Alamar Biosciences Reports First Quarter 2026 Financial Results
<p>FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling